Skip to content

Pain Relief Study of Ultrasound Guided Transverse Abdominis Plane(TAP)Block

Analgesic Efficacy of Ultrasound Guided Transversus Abdominis Plane Block After Cesarean Delivery in Patients With a BMI > 30

Status
Withdrawn
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01217580
Acronym
TAP
Enrollment
0
Registered
2010-10-08
Start date
2010-10-31
Completion date
2011-10-31
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cesarean Section

Keywords

c-section, cesarean section, TAP block, pain, pain after delivery, pain after C-section, pain after C-section delivery, pain after cesarean delivery, pain after cesarean

Brief summary

The purpose of this study is to determine if injecting a local anesthetic, or numbing medication, above each hip will decrease the amount of narcotic pain medicine that is typically required by a patient after a cesarean delivery. Ultrasound pictures will be used to guide placement of this injection. Either ropivicaine (a type of numbing medication called a local anesthetic) or a placebo (saline) will be injected. For 24 hours, you will be given a button to press when you have pain. When the button is pressed, you will be given a small amount of pain medication called hydromorphone through your IV. You will also be given a pain medication called ketorolac through your IV every 8 hours for 24 hours after surgery.

Interventions

20ml each side of the hip of 0.5% ropivacaine into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery

DRUG0.9% sodium chloride

20ml each side of the hip of 0.9% sodium chloride into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery

Sponsors

Ochsner Health System
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age 18 years or over * ASA class 1 , 2 or 3 * BMI greater than 30 kg/m2 (as recorded at the patient's last clinic appointment or as measured on the day of delivery) * Scheduled for cesarean section via Pfannenstiel incision (with or without a tubal ligation) * 150 cm or taller * Informed consent obtained

Exclusion criteria

* ASA class 4 * Age under 18 * Relevant drug allergy * Contraindication to spinal anesthesia * Height \< 150 cm * Patient receiving medical therapies considered to result in a tolerance to opioids * Any other major surgical procedure performed other than cesarean delivery with or without tubal ligation * Patient with relevant contraindications to ketorolac, such as history of gastrointestinal bleeding or impaired renal function * Patient refusal

Design outcomes

Primary

MeasureTime frame
hydromorphone consumed by patient controlled analgesia in the first 24 hours after cesarean delivery24 hours

Secondary

MeasureTime frame
Categorical pain scores and Visual Analog Scale (VAS) pain scores (at rest and with movement), nausea and sedation will be assessed to evaluate narcotic side effects24 hours

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026